Similarly, previous studies had stated that ASPM, CDC20, BUB1B, and CDCA8 expression could be potential poor survival prognostic biomarkers in lung adenocarcinoma [14], prostate/breast cancer [18,19], glioblastoma [12], respectively. This evidence concerns the gene ASPM and lung adenocarcinoma.